ADX10059 Anxiety Data

Study 202: Design

- 50 patients undergoing elective dental procedure at specialist U.K. centers in a Phase IIa trial
  - All patients had moderately severe dental anxiety
  - 27 received a single dose of ADX10059 250 mg
  - 23 received a single dose of placebo
  - ADX10059 or placebo were administered orally 60 minutes prior to a dental procedure
- Primary endpoint: VAS at 60 minutes
- Secondary endpoints:
  - VAS at other time points
  - skin conductance at multiple time points
  - patient ratings of medication

Study 202: Outcome

- Primary endpoint: VAS at 60 minutes not statistically significant
- No statistical significance on VAS at other time points
- A trend on skin conductance starting 60 minutes after administration
- Positive patient ratings of study medication effectiveness

Conclusion:

- ADX10059 did not demonstrate benzodiazepine like effects in acute anticipatory anxiety however the effects observed suggest ADX10059 may have efficacy in other types of anxiety (e.g. GAD, where fenobam has shown clinical efficacy)

Allosteric Modulator Pipeline

addex Pharmaceuticals



NAM = negative allosteric modulator
PAM = positive allosteric modulator

addex Pharmaceuticals

allosteric modulators for human health

Q&A

www.addexpharma.com